Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000541237 | SCV000644491 | benign | Tuberous sclerosis 2 | 2023-05-12 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000764029 | SCV000894983 | uncertain significance | Lymphangiomyomatosis; Isolated focal cortical dysplasia type II; Tuberous sclerosis 2 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001021518 | SCV001183144 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-12-19 | criteria provided, single submitter | clinical testing | The p.D1319V variant (also known as c.3956A>T), located in coding exon 32 of the TSC2 gene, results from an A to T substitution at nucleotide position 3956. The aspartic acid at codon 1319 is replaced by valine, an amino acid with highly dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000541237 | SCV002040798 | uncertain significance | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV001021518 | SCV002533472 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-08-27 | criteria provided, single submitter | curation | |
Tuberous sclerosis database |
RCV000042782 | SCV000066578 | not provided | Tuberous sclerosis syndrome | no assertion provided | curation |